Earnings Releases·Oct 27, 2026, 7:04 AM ET

Repligen Corporation — Third Quarter 2026 Earnings Summary

Q3 2026 revenue reached $209.3 million (11% YoY, 12.5% organic), while GAAP net loss was $38.4 million driven by a $41.2 million intangible asset impairment; adjusted EPS rose to $0.53 from $0.46 YoY.
Full-year 2026 guidance was raised to $844 million–$852 million revenue and $2.05–$2.09 adjusted EPS, reflecting 14.5%–15.5% reported growth and the inclusion of BioLife Solutions from its October 6 closing date.
The company completed the BioLife Solutions acquisition to expand its cell therapy consumables platform and divested Polymem, with early integration feedback described as encouraging and synergy realization underway.
Cash and marketable securities increased to $863 million as of September 30, 2026, while management cited strong order momentum and improving end-market demand across consumables, services, and capital equipment.